Toll Brothers Apartment Living® Opens Brand-New Community in Frisco

Move Marks Company’s First Multifamily Community Opening in Texas

FORT WASHINGTON, PA, Feb. 01, 2021 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE: TOL) (www.TollBrothers.com), the nation’s leading builder of luxury homes, through its Toll Brothers Apartment Living® rental subsidiary, and partner Daiwa House Texas Inc., a subsidiary of the largest single-family homebuilder in Japan, Daiwa House Group, is excited to announce the opening of Kilby, the company’s first multifamily community in Texas. Located in Frisco, Kilby is the first of many upcoming community openings in Dallas-Fort Worth market for Toll Brothers Apartment Living. 

Kilby, a 258-apartment home community located in Frisco Square, offers one- and two-bedroom floor plan styles. The community provides numerous amenities for residents to enjoy including a luxury-style pool, outdoor kitchen & bar, clubroom, fitness center, pet spa, and much more. These amenities drive resident connection and entertainment throughout the community. From keyless entry to light-filled spaces, the apartment homes have been thoughtfully designed with the residents in mind. Apartment home features include quartz countertops, stainless steel appliances, wood-style flooring in living areas, plush carpet in bedrooms, Texas-sized closets, community-wide WiFi and a HD local TV channel package.

“We’re excited to bring our luxury apartment communities to Frisco, one of the fastest growing cities in the country,” said Tommy Rhodus, Regional Director of Acquisitions and Development, Toll Brothers Apartment Living. “Kilby is conveniently situated for residents to explore the many activities that are offered in the neighborhood.”

Located in the heart of Frisco Square, residents of Kilby will enjoy the charming neighborhood complete with local restaurants, boutique shops, and entertainment. Frisco is home to several professional sports headquarters, a unique creative arts scene, and is situated in the highly-rated Frisco Independent School District. Within a short walking distance of Kilby, residents can enjoy an FC Dallas game or concert at Toyota Stadium, discover antique cars at the Frisco Heritage Museum, explore art galleries at the Frisco Discovery Center, or watch a play at the Black Box Theater.

“As we enter the DFW market, we celebrate Toll Brothers Apartment Living’s tremendous growth in the southern and central markets,” said Charles Elliott, President, Toll Brothers Apartment Living. “We look forward to expanding into dynamic neighborhoods throughout Texas.”

Toll Brothers Apartment Living manages the development and marketing of Kilby. For more information regarding Kilby, please visit their website: www.livekilby.com

ABOUT TOLL BROTHERS APARTMENT LIVING®

Toll Brothers Apartment Living (TBAL) is the apartment development division of Toll Brothers, Inc. (NYSE: TOL), an award-winning Fortune 500 company and the nation’s premier builder of luxury homes. Toll Brothers Apartment Living is bringing the same quality, value, and service familiar to luxury home buyers throughout the country to upscale urban and suburban rental communities in select markets, including Atlanta, Boston, Dallas, Los Angeles, New York, Philadelphia, Phoenix and Washington, DC. Toll Brothers Apartment Living has developed more than 6,400 units, has more 4,100 units under management and controls a national pipeline of more than 16,000 units. Toll Brothers Apartment Living communities combine the energy of vibrant locations with unparalleled amenities, resident services, design, and the expertise of the nation’s leading builder of luxury homes. For more information visit TollBrothersApartmentLiving.com

ABOUT DAIWA HOUSE TEXAS INC. 

From its humble beginnings in the early 1950s creating small, affordable prefabricated housing to its status now as the largest single-family homebuilder in Japan, the Daiwa House Group continues to make strides in the United States by fulfilling its corporate mission of effective leadership, innovation and environmentalism through its wholly owned subsidiary: Daiwa House Texas. Founded in 2011, the firm has already established a reputation for quality and excellence by developing premiere multifamily properties in most major metro areas across the country and, after the acquisition of Stanley Martin by Daiwa House Group in 2016, construction of scores of robust single-family homes throughout the East Coast. In the coming decades, Daiwa House Group and Daiwa House Texas look forward to continuing their goal of partnering with developers to provide Americans with superior places to live.


# # #

Attachments



John M. Piedrahita
Toll Brothers Apartment Living
202-378-3302
[email protected]

Celebrating Black Voices, Past and Present, in The Palm Beaches

During Black History Month and beyond, Florida’s Cultural Capital® is spotlighting Black artists

Lake Worth Beach, Fla., Feb. 01, 2021 (GLOBE NEWSWIRE) — Black History Month is a time to honor, celebrate and amplify Black voices. The Cultural Council for Palm Beach County and its many cultural partners are focused on equity and inclusion in the cultural sector. This month and throughout the season, enjoy a variety of exciting programs that celebrate the many achievements of people of color — from local artists to international jazz musicians, Civil Rights leaders and more.

Below is a selection of upcoming Black History Month programming and exhibitions in The Palm Beaches:

What: “Art Finds a Way
Where: Norton Museum of Art (West Palm Beach)
Description: The exhibition features works by artists including Nina Chanel Abney, Kara Walker, Hank Willis Thomas, Faith Ringgold, and others, whose art references historic and personal experiences as well as popular culture and the media to address persistent contemporary issues of racial injustice. A section of the exhibition will be devoted to art that may be interpreted differently during this time, offering solace and reflection as we endure the COVID-19 pandemic, including work by Njideka Akunyili Crosby, Dan Flavin and Jaye Rhee.
When: Now through May 30, 2021
Cost: Members: Free; Adults: $18; Seniors (60 and up): $15; Students with valid school ID: $5; Children 12 and under: Free

What: “Soul on Art: Ghosts of Africa”
Where: Lighthouse ArtCenter Gallery (Tequesta)
Description: This exhibit features paintings, sculptures and multimedia by Black and Brown artists in the world today, including Leonardo Drew, Adam Pendleton, William Kwamena-Poh, Ransome, Kara Walker and Purvis Young. It showcases the personal experience and cultural heritage of these artists. While some of the pieces are on loan from private collections, many are available for purchase.
When: Now through March 10, 2021
Cost: Free for members; $5 suggested donation for non-members

What:
“City of Hope: Resurrection City and the Poor People’s Campaign”

Where: Historical Society of Palm Beach County (West Palm Beach) 
Description: This exhibit honors Dr. Martin Luther King Jr.’s final and most ambitious vision that each U.S. citizen have equal access to economic opportunities and the American dream. It examines the 1968 Poor People’s Campaign, which was a grassroots, multiracial movement that drew thousands of people to Washington, D.C. for 43 days where demonstrators demanded social reforms while living in a tent city known as Resurrection City. This exhibit highlights protest signs and political buttons, as well as newly discovered photographs. It was organized by the Smithsonian and the National Museum of African American History and Culture.
When: Now through February 25, 2021
Cost: Free

What:
“Jazz: The Joan Cartwright Collection”

Where: Spady Cultural Heritage Museum (Delray Beach) 
Description: In its newest exhibition, the Spady Museum displays the art collection of local jazz veteran and historian/scholar Dr. Joan Cartwright, whose vault includes photos, paintings and artwork by Charles Mills, featuring Black jazz and blues musicians. The exhibit also features instruments and albums from local Delray Beach donors.
When: Through February 28, 2021
Cost: Free, donations welcome

What:
New Wave Artist-In-Residence Program: Joiri Minaya

Where: Rosemary Square (West Palm Beach) 
Description: Joiri Minaya, a Dominican-United Statesian, is a multi-disciplinary visual artist. Her works destabilize historic and contemporary representations of an imagined tropical identity. Minaya’s work explores the performativity of tropical identity as a product: the performance of labor, decoration, beauty, leisure, service and the (female, Brown, Black) body within it all. 
When: February 15-March 31, 2021
Cost: Free

What:
“Karibu: A Celebration of Black Artists in Palm Beach County”

Where: Cultural Council for Palm Beach County (Lake Worth Beach)
Description: Karibu (pronounced kah-ree-boo) means “welcome, come in” in Swahili. This celebratory concept of Black culture, not unlike the Southern tradition of Sunday dinner after church, invites everyone to embrace the journey of life and learn through the eyes and creativity of local Black artists. This Harlem Renaissance-style exhibition is intended to build cultural bridges (not walls) between different communities.
When: Now through March 13, 2021 (Tuesdays through Fridays)  
Cost: Free

*If you plan on traveling, please note that cultural organizations in The Palm Beaches recognize that safety is a top priority for visitors. Palm Beach County currently has a local ordinance requiring facial coverings in public places, indoors or outdoors, wherever social distancing isn’t possible. Local cultural organizations also have specific guidelines right now to help keep guests safe, and many have signed The Palm Beaches Pledge, promising to follow guidelines from health and government officials to prevent the spread of COVID-19 and keep everyone safe. Please refer to each organization’s website for updates and details before visiting. 

For information on virtual and in-person more happenings in The Palm Beaches, visit palmbeachculture.com/events.

###

About Florida’s Cultural Capital®
The Palm Beaches is a collection of 39 cities and towns stretching from Boca Raton to Jupiter and Tequesta, with 47 miles of pristine Atlantic Ocean beaches and sophisticated art and culture. The destination has more than 200 cultural organizations that produce 42,000 events, exhibitions and performances annually.

The Cultural Council for Palm Beach County is the official support agency for arts and culture in The Palm Beaches, Florida’s Cultural Capital®. Headquartered in the historic Robert M. Montgomery, Jr. Building in Downtown Lake Worth Beach, the Council presents exhibitions and performances featuring artists who live or work in Palm Beach County. The building also serves as a VISIT FLORIDA-designated Florida Certified Tourism Information Center, a helpful resource for visitors. The Council’s complimentary Cultural Concierge program provides visitors with expert recommendations, custom itineraries and enhanced access to local events, talent and venues.

Attachment



Hannah Deadman-Arnst
Cultural Council for Palm Beach County
561-471-1602
[email protected]

KESSLER TOPAZ MELTZER & CHECK, LLP: Final Deadline Reminder for SPLUNK INC. Investors – SPLK

RADNOR, Pa., Feb. 01, 2021 (GLOBE NEWSWIRE) — Kessler Topaz Meltzer & Check, LLP reminds Splunk Inc. (NASDAQ: SPLK) (“Splunk”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of those who purchased or acquired Splunk common stock between October 21, 2020 and December 2, 2020, inclusive (the “Class Period”).



FINAL DEADLINE REMINDER



:


Splunk


investors may,



no later than February 2, 2021



, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; toll free at (844) 887-9500; via e-mail at



[email protected]



; or click

https://www.ktmc.com/splunk-inc-securities-class-action?utm_source=PR&utm_medium=link&utm_campaign=splunk#overview

According to its filings with the SEC, Splunk “provides innovative software solutions that ingest data from different sources including systems, devices and interactions, and turn[s] that data into meaningful business insights across the organization.” Splunk states that its “Data-to-Everything platform enables users to investigate, monitor, analyze and act on data regardless of format or source.”

The Class Period commences on October 21, 2020, when Splunk held a call with several analysts at the Virtual Analyst & Investor Session at .conf.20. On this call, Splunk assured investors that everything was on track for the close of the third quarter, which was just ten days after the call.

However, the truth regarding its third quarter was revealed after the market closed on December 2, 2020, when Splunk announced its financial results for its third fiscal quarter for 2021. In its announcement, Splunk reported total revenues of $559 million, down 11% year-over-year and which missed estimates by nearly $60 million. Furthermore, Splunk announced quarterly non-GAAP earnings per share of -$0.07, missing estimates by $0.15, as well as GAAP earnings per share of -$1.26, missing by $0.24 per share.

Following this news, shares of Splunk common stock fell, closing at $158.03 per share on December 3, 2020, down over 23% from the December 2, 2020 closing price of $205.91 per share.

The complaint alleges that, throughout the Class Period, the defendants misrepresented and/or failed to disclose to investors that: (1) Splunk was not closing deals with its largest customers in the third fiscal quarter of 2021; (2) Splunk was not hitting the financial targets it had previously announced; and (3) as a result of the foregoing, the defendants’ public statements were materially false and misleading at all relevant times.

Splunk investors may, no later than February 2, 2021, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP, or other counsel, or may choose to do nothing and remain an absent class member.  A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.  In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. 

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world.  The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars).  The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(844) 887-9500 (toll free)
(610) 667-7706
[email protected]



Impeach, Indict, Heal? A Discussion of Post-Trump Washington

CommPRO and The Museum of Public Relations present the new podcast, “That Said with Michael Zeldin”

New York, Feb. 01, 2021 (GLOBE NEWSWIRE) — As we draw close to the start date of former President Trump’s second impeachment trial many questions require answers and in depth analysis. Over the course of two podcast episodes, we have spoken to Impeachment Manager Congressman Eric Swallwel, Constitutional Law Professor Michael Gerhardt, former President Bill Clinton’s Press Secretary during his impeachment saga, Joe Lockhardt, former Republican Congressman Charlie Dent to help us understand and process the events that gave rise to the impeachment, what to expect during the trial, and  what Washington in the post-Trump era will look like. Please join us for these discussions and then email us at [email protected] for follow up questions and answers. 

A Message from Michael…


That Said
 is a weekly series that takes a fresh look at the ideas, events, and people who shape our times. Join me in lively conversation with bestselling authors, thought leaders, and opinion-makers as we delve into current and evolving topics.

About Our Host

Michael Zeldin is a well-known and highly-regarded TV and radio analyst/commentator.

He has covered many high-profile matters, including the Clinton impeachment proceedings, the Gore v. Bush court challenges, Special Counsel Robert Muller’s investigation of interference in the 2016 presidential election, and the Trump impeachment proceedings. 

In 2019, Michael was a Resident Fellow at the Institute of Politics at the Harvard Kennedy School, where he taught a study group on Independent Investigations of Presidents.

Previously, Michael was a federal prosecutor with the U.S. Department of Justice. He also served as Deputy Independent/ Independent Counsel, investigating allegations of tampering with presidential candidate Bill Clinton’s passport files, and as Deputy Chief Counsel to the U.S. House of Representatives, Foreign Affairs Committee, October Surprise Task Force, investigating the handling of the American hostage situation in Iran.

Michael is a prolific writer and has published Op-ed pieces for CNN.com, The Wall Street Journal, The New York Times, The Hill, The Washington Times, and The Washington Post.

Follow Michael on Twitter @MichaelZeldin





Fay Shapiro
CommPRO.biz
[email protected]

IIROC Trading Resumption – EVER

Canada NewsWire

VANCOUVER, BC, Feb. 1, 2021 /CNW/ – Trading resumes in:

Company: Evergold Corp.

TSX-Venture Symbol: EVER

All Issues: Yes

Resumption (ET): 2:00 PM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

Award-Winning Author Margaret Atwood to Keynote “Unite & Rise” Virtual Celebration to Benefit Fairfield County’s Community Foundation’s Fund for Women & Girls

Annual Fundraiser to Highlight New Signature Initiative — the emme coalition — Connecting Women and Girls in Bridgeport with Lifelong Tools for Wellbeing

Norwalk, Connecticut, Feb. 01, 2021 (GLOBE NEWSWIRE) —

(Norwalk, CT) – Award-winning author of The Handmaid’s Tale and The Testaments, Margaret Atwood, will be the keynote speaker for the Fairfield County’s Community Foundation’s (FCCF) annual celebration for its Fund for Women & Girls in April. “Unite & Rise: A Virtual Celebration for the Fund for Women & Girls,” will begin at 5:30 p.m. on April 16th. Individual tickets and sponsorship packages are available for purchase here.

 

The annual fundraiser will also mark the official introduction of the emme coalition, the Fund for Women & Girls’ new signature initiative in partnership with OPTIMUS Health Care. A research-driven program for girls and women aged 12 to 49 in Bridgeport, the emme coalition will coordinate physical wellness, behavioral health and social services to give women and girls lifelong tools for wellbeing that can be passed along to future generations.

 

The emme coalition — “emme” stands for empowerment, mindfulness, motivation and education — will provide one-stop virtual and in-person services to girls and women in Bridgeport. emme will take a holistic approach to address barriers that prevent women and girls from receiving quality healthcare and reaching their full potential. By offering program participants a broad range of options and possibilities, it will help them make informed choices as partners in their own care.

 

“We are thrilled that we will be able to hear from Margaret Atwood, who is known for her distinct and outspoken perspective on feminism and her views on power,” Juanita James, President & CEO of Fairfield County’s Community Foundation, said. “Her rich experience and view of the world for women is especially welcome as we launch the emme coalition, a program that will give young women access to lifelong tools for wellbeing.” 

 

“We are pleased to be part of this important initiative for women & girls. Being community based, OPTIMUS has the resources to be supportive and guide career and personal choices. Women are the rocks of any family and their wellbeing pays dividends for all their members.” Ludwig Spinelli, CEO, OPTIMUS Health Care, Inc.

 

Atwood had been slated to speak at the Fund for Women & Girls annual luncheon in April 2020, which was cancelled due to the coronavirus pandemic. She has written more than 50 books of fiction, poetry

 

and critical essays. Her most recent, The Testaments, won the 2019 Booker Prize. The Handmaid’s Tale has been the basis of a critically acclaimed television series. Her other works include the Booker Prize-shortlisted Oryx and Crake, Alias Grace, The Robber Bride, Cat’s Eye and Booker winner, The Blind Assassin.

 

The Community Foundation’s Fund for Women & Girls is in its 23rd year and is the largest women’s fund in New England. The Fund’s work has improved the lives of thousands of women and girls in the region with more than $8 million in grants. This year’s virtual evening event comes in place of the Fund’s annual luncheon, which attracts more than 800 enthusiastic supporters each year and has featured speakers such as Dr. Maya Angelou, Gloria Steinem, Billie Jean King and Tracee Ellis Ross. 

 

As a partner in the emme coalition, OPTIMUS Health Care will provide holistic services to help young women set life goals and make plans to achieve them through healthy lifestyle choices, self-advocacy, optimizing employment and making sound financial decisions. The emme coalition will serve 100 women and girls through intensive case management, and another 1,000 with less intensive services.

 

About Fairfield County’s Community Foundation

Fairfield County’s Community Foundation promotes philanthropy as a means to create change in Fairfield County, focusing on innovative and collaborative solutions to critical issues impacting the community. Individuals, families, corporations and organizations can establish charitable funds or contribute to existing funds. The Community Foundation is in compliance with the Council on Foundations’ national standards and has awarded over $337.5 million in grants to nonprofits in Fairfield County and beyond since 1992. As a trusted nonprofit partner and thought leader, the organization brings together community organizers, business experts, and philanthropists to close the opportunity gap in Fairfield County with a focus on eliminating disparities in education, employment, housing, and health. Our goal is to create a vital and inclusive community, where every individual has the opportunity to thrive. Learn more at FCCFoundation.org and follow us on Facebook, Twitter and LinkedIN.  Listen to the Fairfield County Thrives podcast at https://fccfoundation.org/podcasts/.

 

 

About OPTIMUS Healthcare
Established in 1976, OPTIMUS Healthcare, Inc., is a Federally Qualified Health Center that provides comprehensive primary care to persons of all ages, regardless of their ability to pay or health insurance status. Its team of licensed healthcare providers and trained professionals utilize innovative techniques and extensive experience to address evolving needs. OPTIMUS Health Centers are Joint Commission and NCQA accredited. Learn more.

 

###

Media Contact

Patty McQueen 860-985-3533; [email protected]

 


Brynne Bartiromo
Fairfield County's Community Foundation
9084622636
[email protected]

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Apollo Global Management, Inc. and Encourages Investors with Losses to Contact the Firm

PR Newswire

LOS ANGELES, Feb. 1, 2021 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Apollo Global Management, Inc. (“Apollo” or “the Company”) (NYSE: APO) for potential breaches of fiduciary duty on the part of its directors and management.

If you are a shareholder, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ongoing-investigation-alert-the-schall-law-firm-announces-it-is-investigating-claims-against-apollo-global-management-inc-and-encourages-investors-with-losses-to-contact-the-firm-301219214.html

SOURCE The Schall Law Firm

OAREX Locks In $50M Bank Debt for Future Digital Payouts

PR Newswire

CLEVELAND, Feb. 1, 2021 /PRNewswire/ — On December 14th, OAREX closed a $50M line of credit with East West Bank, an FDIC insured institution. This new capital brings OAREX’s total line of credit to $100M, with the other $50M secured from Arena Investors of New York in July, 2019.


$100M to Buy Future Digital Payouts

OAREX will use the funds to continue to buy future digital payouts from online businesses. Access to liquidity for a rapidly growing online business is necessary to sustain growth, because their models are capital intensive.

Many internet-based businesses are dependent on capital because of the long payout terms associated with digital revenue. Sometimes, an online business can wait as long as 120 days to collect on sales. That’s where OAREX comes into play.

Trade In a Digital Payout, Get Capital Now

When an online business gets paid up front, they can buy more users and traffic, in turn driving more sales. The problem is they have to wait.

With OAREX’s future digital payouts product, online businesses can get paid now, and reinvest the same dollar multiple times, instead of waiting 30-120 days. This allows OAREX users to turn the same dollar over and over again, increasing total return on ad spend (ROAS). That means more scale, faster.

How OAREX’s Future Digital Payouts Works

Through OAREX, users can realize future digital revenue as earned, on a daily, weekly, or monthly basis, rather than waiting 30-90+ days.

The first step for users is to open an account in 30 seconds or less. Users can then connect digital revenue dashboards to verify data. Within minutes, users get an offer from OAREX, with the first funding in 72 hours or less.

Once a user is on the exchange, OAREX’s funding is on-demand and paid within the hour. If a user needs capital, they simply sell the future digital payout and funds appear in their account. OAREX reports all digital revenue and payout data on a daily basis, via its platform.

OAREX Specializes in Funding Internet Businesses

As a Capital-as-a-Service company, OAREX understands the risks associated with online businesses. This allows users on the exchange to get better terms from OAREX, than what they would get elsewhere.

Users can create an account and get started at oarex.com/products/future-digital-payouts. Referral partners, who get paid a user royalty for the life of any referred deals, can sign-up at oarex.com/partner-with-us.

About OAREX Capital Markets, Inc.

OAREX operates a digital revenue exchange where online businesses can exchange future revenue events for capital now. Established in 2013, OAREX has become a worldwide leader in financing for online businesses. East West Bank’s investment in OAREX is a testament to its model and the online market as a whole. See oarex.com for more information.

About East West Bank

East West Bancorp is a publicly owned company with total assets over $53 billion and is traded on the Nasdaq Global Select Market under the symbol “EWBC”. The Company’s wholly owned subsidiary, East West Bank, is one of the largest independent banks headquartered in California.  East West Bank’s Structured Finance group provides senior secured lending facilities to specialty finance companies and project finance transactions. For more information about East West Bank, please visit www.eastwestbank.com

Arena Investors, LP

Arena Investors is an institutional asset manager with $1.7 billion of committed assets under management as of November 1, 2020, that provides creative solutions for those seeking capital in special situations. The firm brings individuals with decades of experience, a track record of comfort with complexity, the ability to deliver within time constraints, and the flexibility to engage in transactions that cannot be addressed by banks and other conventional financial institutions. Arena Investors’ mandate is global, and also unconstrained in terms of asset class and industry. Based in New York City, Arena was formed in partnership with The Westaim Corporation, a publicly traded Canadian holding company focused on the financial services industry. See www.arenaco.com for more information. 

 

SOURCE OAREX Capital Markets, Inc.

Avivagen Inc. Announces Filing of Preliminary Prospectus for Previously Announced $7.5 Million Bought Deal Unit Offering

Avivagen Inc. Announces Filing of Preliminary Prospectus for Previously Announced $7.5 Million Bought Deal Unit Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

OTTAWA, Ontario–(BUSINESS WIRE)–
Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announced today that it has filed a preliminary short form prospectus with the securities regulators in Ontario, British Columbia and Alberta in connection with its previously announced offering of 15,000,000 units of the Company (the “Units”) on a “bought deal” basis, at a price of $0.50 per Unit (the “Offering Price”) for aggregate gross proceeds of $7,500,000 (the “Offering”). Bloom Burton Securities Inc. (the “Underwriter”) is acting as underwriter for the Offering.

Each Unit shall consist of one common share in the capital of the Company (each a “Common Share”) and one half of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will be exercisable to acquire one Common Share for a period of 36 months following the closing of the Offering at an exercise price of $0.75 per share.

The net proceeds of the Offering will be used to fund research and development expenses, sales and marketing costs, product registration, interest expense, working capital and general corporate purposes. The Offering is expected to close on or about February 16, 2021 or such other date as the Company and the Underwriter may agree, and is subject to certain closing conditions, including but not limited to, the receipt of all necessary regulatory, stock exchange and other approvals, including the approval of the TSX Venture Exchange.

In connection with the Offering the Underwriter will receive: (i) a cash fee equal to 7.0% of the gross proceeds of the Offering; and (ii) that number of broker warrants equal to 7.0% of the Units sold under the Offering, each entitling the holder to acquire one Common Share at the Offering Price for a period of 24 months after the closing.

The Units will be offered pursuant to National Instrument 44-101 – Short Form Prospectus Distributions to qualify the distribution of the Offered Units in each of the provinces of British Columbia, Alberta, and Ontario, and may be offered in such other jurisdictions as the Company and the Underwriter may agree.

The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended and may not be offered or sold within the United States or to, or for ‎the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. ‎registration requirements. This press release does not constitute an offer for sale of securities, nor a solicitation ‎for offers to buy any securities in the United States, nor in any other jurisdiction in which such offer, solicitation or sale would be unlawful. Any public offering of securities in the United States must be made by means of ‎a prospectus containing detailed information about the Company and management, as well as financial ‎statements.‎

About Avivagen

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications. By unlocking an overlooked facet of βcarotene activity, a path has been opened to safely and economically support immune function, thereby promoting general health and performance in animals. Avivagen is a public corporation traded on the TSX Venture Exchange under the symbol VIV, and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

Notice Regarding Forward Looking Statements

This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Avivagen to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include the anticipated closing of the Offering, the anticipated closing date of the Offering, the potential to issue securities in other jurisdictions and the anticipated use of proceeds. The closing of the Offering is subject to a number of customary conditions, including the approval of the applicable securities commissions and the TSX Venture Exchange, some of which are outside the control of Avivagen and the Underwriter. If the Offering does close, circumstances may necessitate or make it desirable that Avivagen use the proceeds of the Offering for different purposes than described above. Readers are directed to the detailed discussion of risk factors related to the Offering that will be set forth in the prospectus filed by Avivagen in connection with the Offering. The forward-looking statements included in this news release are made as of the date of this news release and Avivagen does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Avivagen Inc.

Drew Basek

Director of Investor Relations

100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6

Phone: 416-540-0733

E-mail: [email protected]

Kym Anthony

Chief Executive Officer

100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6

Head Office Phone: 613-949-8164

Website: www.avivagen.com

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Science Veterinary Agriculture Research Natural Resources General Health Health Other Natural Resources

MEDIA:

Genprex Issues Shareholder Letter and Provides Corporate Update

Genprex Issues Shareholder Letter and Provides Corporate Update

Major milestones achieved in advancing gene therapies for lung cancer and diabetes

Company looks toward launching key clinical trials in lung cancer in 2021

AUSTIN, Texas–(BUSINESS WIRE)–Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced today that it has issued a shareholder letter and corporate update outlining the Company’s developments and initiatives for 2020 and anticipated milestones for 2021 and beyond.

“We achieved many significant milestones in 2020 that have set the stage for a transformational 2021,” said Rodney Varner, President and Chief Executive Officer of Genprex. “The primary focus this past year was on the preparation for our two lead clinical trials in non-small cell lung cancer (NSCLC). Our Acclaim-1 clinical trial will combine REQORSA with Tagrisso® for patients with late stage NSCLC whose disease progressed after treatment with Tagrisso. Our Acclaim-2 clinical trial will combine REQORSA with Keytruda® for NSCLC patients who are low expressors (1% to 49%) of the protein programmed death-ligand 1 (PD-L1). We remain on track to initiate both trials in the first-half of 2021. Additionally, the $40 million-plus in capital infusions in 2020 have provided us with a strong balance sheet as 2021 begins. We are grateful for the confidence and support of our shareholders and look forward to executing on our strategies to achieve a number of potentially value-creating milestones.”

To read the letter in its entirety, a digital copy of the Company’s Shareholder Letter can be found on the Company’s website here.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone.

For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current, regarding the Company’s future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of REQORSA™ immunogene therapy drug, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining any FDA approvals of REQORSA and our other potential product candidates including whether we receive necessary approvals to commence clinical trials or benefit from fast track or similar regulatory designations; costs associated with developing our product candidates, whether we identify and succeed in acquiring other technologies and whether patents will ever be issued under patent applications that are the subject of our license agreements or otherwise. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Genprex, Inc.

(877) 774-GNPX (4679)

Investor Relations

GNPX Investor Relations

(877) 774-GNPX (4679) ext. #2

[email protected]

Media Contact

Genprex Media Relations

Kalyn Dabbs

(877) 774-GNPX (4679) ext. #3

[email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo
Logo